Injecting Innovation: The Rising Trend of Autoinjectors in Modern Medicine

Autoinjector are medical devices that enable the rapid and safe delivery of drugs through different administration routes. They are designed to offer patients a convenient and effective means of self-administering medications, particularly in emergency situations and chronic conditions (that require frequent injections). Further, various advancements, such as hidden or retractable needles (which mitigate the risk of accidental needle sticks) , user-friendly designs featuring ergonomic grips, and audible and visual indicators, have notably enhanced their usability, safety and dependability of autoinjectors. Additionally, connectivity features enable the patients and healthcare providers to monitor medication usage, adherence and outcomes, further bolstering their effectiveness. Roots Analysis added The autoinjectors market research report forecast period from 2024 to 2035.

Autoinjectors Features

Overall, the advancements in autoinjector technology, coupled with their ease of use and safety features, have contributed to their increasing adoption across various healthcare settings, benefiting both patients and healthcare providers alike. The continuous evolution of autoinjectors reflects a significant shift towards empowering patients to take control of their treatment, ensuring timely and accurate medication delivery for better health management.

Autoinjectors Market Manufacturers & Current Landscape

Presently, close to 150 autoinjectors have been commercialized / being developed by more than 50 players for the treatment of various therapeutic areas, including diabetes, multiple sclerosis and rheumatoid arthritis.

The autoinjectors market is highly fragmented, featuring the presence of both established companies as well as emerging start-ups. Examples of companies having a strong foothold in this industry include Becton, Dickinson and Company (BD), Gerresheimer, Haselmeier and West Pharmaceutical Services. Further, majority of the companies engaged in this domain are presently headquartered in North America, followed by Europe.

Notably, majority of the autoinjectors have been / are being developed to deliver fixed doses of medication; this ensures consistent medication dosage and thereby reducing any dosage related errors. Further, certain autoinjectors have the capability to deliver both fixed and variable doses, thereby offering the user more flexibility to use.

Autoinjectors Capability

Key Initiatives in the Autoinjectors Market Domain

A. Partnerships:

Stakeholders in this domain are known to adopt a variety of partnership models in order to collaborate with other companies / organizations. Such deals are inked to not only allow companies to expand their respective product portfolios, but also gain additional capabilities related to emerging technologies. Notably, product development agreements emerged as the most popular type of partnership model adopted by stakeholders in the autoinjectors domain.

Stakeholders in the Autoinjectors

Examples of some partnerships in this domain include:

  • In January 2024, SHL Medical partnered with FUJIFILM Diosynth Biotechnologies to enhance the former company’s manufacturing capabilities for their Molly autoinjectors. Through this partnership, the latter company aims to provide pre-validated final assembly services of Molly autoinjectors, to increase manufacturing capacity up to 30 million units per year, starting in early 2025.
  • In January 2024, Rx Bandz signed a manufacturing agreement with Weiss-Aug for their MiniJect autoinjector. This partnership is likely to allow Rx Bandz to scale up production of the MiniJect autoinjector to meet the anticipated demand in coming years.
  • In September 2023, Ypsomed partnered with Novo Nordisk to supply large quantities of their YpsoMate autoinjector. The collaboration aims to support Ypsomed’s growth strategy and enable the treatment of individuals with chronic conditions and is expected to contribute to commercial sales starting in the 2025/26 financial year.
  • In July 2023, Crossject partnered with AFT Pharmaceuticals for licensing, distribution and promotion of ZENEO Midazolam for patients with epileptic seizures in Australia and New Zealand.

B. Patents:

Over the past years, industry stakeholders and researchers have been extensively working towards the integration of advanced features in autoinjectors. As a result, more than 1,100 patents have been granted / filed related to this domain by various industry and non-industry players, demonstrating the heightened pace of research in this domain.

Distribution of Patents

It is worth mentioning that patent filing has increased rapidly at a CAGR of 29%, between 2019 and 2023. Further, most of the patents (52%) in this domain were patent applications (not having received approval yet), followed by granted patents (40%). North America emerged as the most prominent region where most of the patents related to autoinjectors were filed / granted.

Key Growth Drivers Autoinjectors Market

  1. Ease of Use: The benefits of using autoinjectors over conventional methods of parenteral drug delivery are widely recognized by healthcare industry professionals as well as end-users. Some of the advantages include convenient usability, enhanced precision, improved sterility, reduced risk of microbial contamination, easy storage and disposal, as well as quick delivery in emergency situations.
  2. Reduced Medication Errors: As the autoinjectors contain the exact dose of medication, they enable reduced dosing errors. Furthermore, many of these devices incorporate electronic panels that offer both audio and visual feedback, keeping users continuously informed about the drug delivery progress.
  3. Economic Advantages: The use of autoinjectors empowers patients to self-administer medications at home, diminishing the necessity for frequent visits to healthcare facilities. This results in cost savings for both patients and healthcare systems, as it reduces transportation expenses, clinic overheads, and staff resources.
  4. Rich and Growing Pipeline of Biologics and Biosimilars: The popularity of biologics is growing continuously in the overall pharmaceutical market; in fact, in the recent times, injectable drug pipeline is shifting from small molecules to complex biologics, such as monoclonal antibodies This trend is likely to increase the demand for autoinjectors, in the coming years.

Key Growth Restraints Autoinjectors Market

  1. Manufacturing Complexities: Autoinjectors comprise of various small, intricate components that require precise manufacturing and assembly processes with tight tolerances to ensure optimal functionality and performance. Given that autoinjectors are predominantly utilized for administering injectable drugs, it’s imperative to maintain a sterile environment throughout the manufacturing process to prevent contamination and ensure end-user safety.
  2. Use Errors: Although manual devices are laborious, they are often considered more reliable. This is because automatic or programmed devices, such as autoinjectors, have several potential points of failure, such as batteries, pump components, needle insertion/retraction mechanisms, or dose programming, which elevate the risk of technical errors. While some of these errors may be inevitable, it is recommended that the patient thoroughly reads through the device manual before use in order to avoid any careless errors.
  3. Concerns Related to Product Recalls in the Past: Autoinjectors are generally safe and convenient; however, manufacturing issues can pose risks to patients’ health and necessitate product recalls. Concerns have increased over time regarding dosing errors, drug stability issues, and device malfunctions, leading to the recall of numerous autoinjector devices.

Concluding Remarks

The pharmaceutical industry is undergoing continuous transformation within the realm of drug delivery, witnessing the emergence of increasingly convenient and patient-friendly systems. As the number of commercially available biologics increases and patents lose their exclusivity, the need for novel delivery devices is also expected to increase. The historical trends of existing delivery devices, such as prefilled syringes, on body injectors, pen injectors and autoinjectors suggest a strong demand in the market. The autoinjectors market is poised to mirror this growth pattern as more individuals transition from traditional to user-centric drug delivery options. Further, the future growth of autoinjector market hinges significantly on the GLP-1 drugs, for the treatment of obesity and type 2 diabetes, empowering patients with enhanced independence, convenience, and oversight over their treatment protocols. These devices have the potential to revolutionize diverse therapeutic domains, marking a significant stride towards patient-centered and value-driven care.

To know more details of the autoinjectors market visit here >> https://www.rootsanalysis.com/reports/autoinjectors-market/293.html